Ask your data questions, get answers you can trust
No SQL. No formulas. Just ask questions in plain language and get reliable instant insights from all your business data.
What was margin by customer last month?
Here are your top 3 customers by margin for last month:
- Acme Corp: 28.4% margin (€142K profit)
- Beta Industries: 24.1% margin (€98K profit)
- Gamma Ltd: 22.8% margin (€87K profit)
Total margin across all customers: 18.7% (+2.1% vs. previous month) Download table Visualize graph
Why did profitability drop in Q3?
I've analyzed the Q3 profitability decline. Here are the key drivers:
1. Raw material costs increased +12% Steel and aluminum prices spiked in August, adding €180K to COGS.
2. Customer mix shifted to lower-margin products Enterprise deals dropped 15%, while SMB volume increased 22%.
3. FX impact of -€120K EUR/USD volatility affected international receivables.
From dashboard to direct answers
Expecta turns your entire BI infrastructure into a conversation, without losing rigor or control, to get you grounded answers.
Natural Language queries
Ask questions in plain English and get instant answers with supporting data.
Auto-generated reports
Describe what you need and AI builds the dashboard for you.
Anomaly detection
AI automatically flags unusual patterns and potential issues.
Insight summaries
Get AI-written summaries of key trends and changes.
No new tools.
Just a connector
The Expecta connector lets your AI access your Power BI data directly. Instead of manually filtering and navigating reports, just ask in plain language and get instant answers from the data you already have access to.
Quick setup
Available as a connector for Claude, ChatGPT, Gemini, Copilot.
Inherits your permissions
Access stays governed by Power BI: everyone sees only the data they are already allowed to see.
Reports and ready-made analyses
Open your dashboards with a link, or read pre-built analyses directly in chat.
Ready to take control of your data?
Expecta is trusted by global private equity firms, international industrial groups and fast-growing scale-ups.